ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“Shape the future of cancer drug development: ESMO TAT represents an excellent opportunity to stay up to date with the latest early phase trials in oncology while learning multi-stakeholder perspectives.
Discuss new data and collaborate with researchers, industry partners, investors, and regulatory bodies.
Register now and save! Early registration deadline: 15 January.”